Telithromycin and Myasthenia Gravis [1]

Clinical Infectious Diseases

Volumn 37, Issue 11, 2003, Pages 1579-

  Nieman, Richard B ^a   Sharma, Kristen ^a   Edelberg, Helen ^a   Caffe, Steve E ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC THERAPY; DISEASE EXACERBATION; DRUG SAFETY; HUMAN; LETTER; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 0344688278     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379617     Document Type: Letter

References (5)

1. Reuters. Aventis urges extreme caution with Ketek in patients with myasthenia gravis [editor's comment]. Clin Infect Dis 2003; 36:ii.
2. Reuters. Aventis urges extreme caution with Ketek in patients with myasthenia gravis [news release], 15 April 2003.
3. Adams SL, Mathews J, Grammer LC. Drugs that may exacerbate myasthenia gravis. Ann Emerg Med 1984; 13:532-8.
4. Howard JF Jr. Adverse drug effects on neuromuscular transmission [review]. Semin Neurol 1990; 10:89-102.
5. US Food and Drug Administration Anti-Infectives Division Advisory Committee Web Site. Aventis Ketek antibiotic rereview. Available at: http: //www.fdatv.com/FDC/AdvisoryCommittee/ Committees/Anti-Infective+Drugs/010803_ Ketek2/default.htm#. Accessed 7 November 2003.